1-4 of 4
Lisa Smith
Close
Sort by
Journal Articles

Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL

Sean D. Reiff, Elizabeth M. Muhowski, Daphne Guinn, Amy Lehman, Catherine A. Fabian, Carolyn Cheney, Rose Mantel, Lisa Smith, Amy J. Johnson, Wendy B. Young, Adam R. Johnson, Lichuan Liu, John C. Byrd, Jennifer A. Woyach
Journal: Blood
Blood (2018) 132 (10): 1039–1049.
https://doi.org/10.1182/blood-2017-10-809020
Published: 2018
Journal Articles

Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia

Neil E. Kay, Susan M. Geyer, Timothy G. Call, Tait D. Shanafelt, Clive S. Zent, Diane F. Jelinek, Renee Tschumper, Nancy D. Bone, Gordon W. Dewald, Thomas S. Lin, Nyla A. Heerema, Lisa Smith, Michael R. Grever, John C. Byrd
Journal: Blood
Blood (2006) 109 (2): 405–411.
https://doi.org/10.1182/blood-2006-07-033274
Published: 2006
Journal Articles

A Novel Celecoxib Derivative, OSU03012, Induces Cytotoxicity in Primary CLL Cells and Transformed B-Cell Lymphoma Via a Caspase and Bcl-2 Independent Mechanism.

Amy Johnson, PhD, Lisa Smith, Jiuxiang Zhu, Nyla Heerema, PhD, Sara Guster, Andrew Mone, MD, PhD, Michael Grever, MD, Ching-Shih Chen, PhD, John Byrd, MD
Journal: Blood
Blood (2004) 104 (11): 3471.
https://doi.org/10.1182/blood.V104.11.3471.3471
Published: 2004
Journal Articles

Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions

Clinical Trials & Observations
Gerard Lozanski, Nyla A. Heerema, Ian W. Flinn, Lisa Smith, Jennifer Harbison, Jennifer Webb, Mollie Moran, Margaret Lucas, Thomas Lin, Marcy L. Hackbarth, John H. Proffitt, David Lucas, Michael R. Grever, John C. Byrd
Journal: Blood
Blood (2004) 103 (9): 3278–3281.
https://doi.org/10.1182/blood-2003-10-3729
Published: 2004